Clinical trials: Metastatic Squamous Cell Carcinoma Neck
Metastatic Esophageal Squamous Cell Carcinoma
A Study of IO Plus Radiotherapy in Patients With Advanced ESCC.
This study is a single-arm, prospective, phase II trial for patients with metastatic esophageal squamous cell carcinoma (ESCC) who received immunotherapy plus chemotherapy as the first-line treatment.
- Trial name
- NCT05760391
- Testing
- Radiotherapy
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Fudan University
Solid Tumor
A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors
This is a first in human, single arm, open label, Phase 1a/1b study to determine the safety, feasibility, and efficacy of a single dose of NeoTCR-P1 T cells in participants with solid tumors.
- Trial name
- NCT03970382
- Testing
- NeoTCR-P1 adoptive cell therapy, nivolumab, IL-2
- Where
- 9 sites in United States
- Volunteers
- 21 people
- Sponsor
- PACT Pharma, Inc.
Head and Neck Cancer
Vaccine Therapy and Celecoxib in Treating Patients With Metastatic Nasopharyngeal Cancer
RATIONALE: Vaccines made from a gene-modified virus and a person's dendritic cells may help the body build an effective immune response to kill tumor cells.
- Trial name
- NCT00589186
- Testing
- Ad5F35-LMP1/LMP2-transduced autologous dendritic cells, celecoxib, flow cytometry
- Where
- Singapore
- Volunteers
- 35 people
- Sponsor
- National Cancer Centre, Singapore
Head and Neck Squamous Cell Carcinoma, Lung Cancer
A Trial of Durvalumab and Tremelimumab in Combination With SBRT in Patients With Metastatic Cancer
The study is an open label, multicentric, Phase I/II trial aiming to evaluate the safety, the clinical activity and abscopal anti-tumor effects of a therapeutic strategy associating Durvalumab in conjunction with SBRT or…
- Conditions
- Head and Neck Squamous Cell Carcinoma, Lung Cancer, Oesophageal Cancer
- Trial name
- ABIMMUNE (NCT03212469)
- Testing
- Durvalumab, Tremelimumab, SBRT
- Where
- France
- Volunteers
- 54 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Squamous Cell Carcinoma of the Hypopharynx
Sorafenib in Combination With Carboplatin and Paclitaxel in Treating Participants With Metastatic or Recurrent Head and Neck Squamous Cell Cancer
This phase II trial studies how well sorafenib works with carboplatin and paclitaxel in treating participants with head and neck squamous cell cancer that has spread to other parts of the body or that has come back.
- Conditions
- Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Squamous Cell Carcinoma of the Hypopharynx, Metastatic Squamous Cell Carcinoma of the Larynx, Metastatic Squamous Cell Carcinoma of the Oral Cavity
- Trial name
- NCT00494182
- Testing
- Carboplatin, Paclitaxel, Sorafenib
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- M.D. Anderson Cancer Center
Triple-Negative Breast Cancer (TNBC), Gastric Cancer (GC)
A Study of MDSY-1240, a STAT3 Degrader, for the Treatment of Hematologic Malignancies and Advanced Solid Tumors
This clinical trial is evaluating a drug called MDSY-2140 in participants with hematologic malignancies and advanced solid tumors.
- Conditions
- Triple-Negative Breast Cancer (TNBC), Gastric Cancer (GC), Gastric Cancer Adenocarcinoma Metastatic, Ovarian Cancer Metastatic
- Trial name
- NCT07899632
- Testing
- MDSY-1240
- Volunteers
- 75 people
- Sponsor
- Medsyn Biopharma, LLC
Advanced/Metastatic Solid Tumors, Colorectal Cancer
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
This is a Phase 1/2 open-label, multi-center, multi-national study with an initial dose escalation part to determine the recommended Phase II dose (RP2D) of MCLA-158 single agent in patients with mCRC.
- Conditions
- Advanced/Metastatic Solid Tumors, Colorectal Cancer, Gastric Cancer, Gastroesophageal-junction Cancer
- Trial name
- NCT03526835
- Testing
- MCLA-158, MCLA-158 + Pembrolizumab, MCLA-158 + FOLFIRI
- Where
- 54 sites in United States, Belgium and 5 more
- Volunteers
- 560 people
- Sponsor
- Genmab
Metastatic Solid Tumor Cancer, Recurrent Head and Neck Cancer
Safety and Efficacy of Intra-Arterial and Intra-Tumoral Ad-p53 With Capecitabine (Xeloda) or Anti-PD-1 in Liver Metastases of Solid Tumors and Recurrent Head and Neck Squamous Cell Cancer
This is a Phase 1/2 study of the combination of Ad-p53 administered intra-arterially in combination with oral metronomic capecitabine or pembrolizumab in patients with unresectable, refractory liver metastases of colorectal…
- Trial name
- NCT02842125
- Testing
- Ad-P53, Xeloda, Keytruda
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- MultiVir, Inc.
Head and Neck Cancer, Unknown Primary Cancer
A Phase 2a, Single-dose, Open-label Study to Evaluate Diagnostic Performance and Safety of Pegsitacianine, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer, in Patients With Unknown Primary Head and Neck Cancer (ILLUMINATE STUDY)
This is a non-randomized, open-label, single-center, safety and imaging feasibility study of Pegsitacianine, an intraoperative fluorescence imaging agent.
- Conditions
- Head and Neck Cancer, Unknown Primary Cancer, Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT05576974
- Testing
- Pegsitacianine
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- University of Texas Southwestern Medical Center
Advanced Cancer, Gastric Cancer
Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or in Combination With Capecitabine in Metastatic Hormone Receptor Positive Breast Cancer
This Phase I/Ib study is a Multicenter, Open-label, Dose-Escalation, Safety, Pharmacodynamic and Pharmacokinetic Study of GZ17-6.02 Monotherapy and in Combination with Capecitabine, Given Orally on a Daily Schedule in Patients…
- Conditions
- Advanced Cancer, Gastric Cancer, Breast Cancer, Pancreatic Cancer
- Trial name
- GEN602 (NCT03775525)
- Testing
- GZ17-6.02, Capecitabine
- Where
- 4 sites in United States
- Volunteers
- 127 people
- Sponsor
- Genzada Pharmaceuticals USA, Inc.
Head and Neck Neoplasms
Study of Monalizumab and Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
The objective of this study is to evaluate in a 3 +3 design, the safety of escalating doses of Monalizumab given IV in combination with cetuximab in patients who have received prior systemic regimen(s) for recurrent and/or…
- Trial name
- NCT02643550
- Testing
- Monalizumab, Cetuximab, Anti-PD(L)1
- Where
- 18 sites in United States, France
- Volunteers
- 143 people
- Sponsor
- Innate Pharma
Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
Optimizing Antitumor Immunity Using Plasmid Electroporation, Pembrolizumab, and Epacadostat
This phase II trial studies how well tavokinogene telseplasmid with electroporation (tavo-EP), pembrolizumab, and epacadostat work in treating patients with squamous cell carcinoma of the head and neck that cannot be removed by…
- Conditions
- Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma, Unresectable Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT03823131
- Testing
- ImmunoPulse, Epacadostat, Pembrolizumab
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Chase Heaton, MD
Head and Neck Squamous Cell Carcinoma
A Study of Nimotuzumab Plus Adebrelimab With Chemotherapy in Cisplatin-Ineligible Patients With Head And Neck Squamous Cell Carcinoma
This is a prospective, single-arm, Phase Ib/II clinical study to evaluate the safety and efficacy of nimotuzumab combined with adebrelimab and chemotherapy in patients with recurrent and metastatic head and neck squamous cell…
- Trial name
- NCT07105592
- Testing
- Nimotuzumab+Adebrelimab+Chemotherapy
- Where
- China
- Volunteers
- 68 people
- Sponsor
- Fudan University
Head and Neck Cancer
Blood Proteins in Predicting Treatment Benefit in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer
RATIONALE: Studying samples of blood in the laboratory may help doctors learn more about cancer. It may also help doctors predict how well patients will respond to treatment.
- Trial name
- NCT00896675
- Testing
- proteomic profiles
- Where
- 3 sites in United States
- Volunteers
- 352 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Head and Neck Cancer
Cisplatin Plus Gemcitabine in Treating Patients With Advanced Squamous Cell Head and Neck Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00003264
- Testing
- cisplatin, gemcitabine hydrochloride
- Where
- 12 sites in United States
- Volunteers
- 22 people
- Sponsor
- Fox Chase Cancer Center
Head and Neck Cancer
The BURAN Study of Buparlisib in Patients With Recurrent or Metastatic HNSCC
The BURAN study is a randomized, open-label phase III study to assess the treatment effect of once-daily buparlisib in combination with weekly paclitaxel compared to weekly paclitaxel alone in patients with refractory, recurrent…
- Trial name
- BURAN (NCT04338399)
- Testing
- Buparlisib & Paclitaxel
- Where
- 162 sites in United States, Argentina and 15 more
- Volunteers
- 487 people
- Sponsor
- Adlai Nortye Biopharma Co., Ltd.
Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell
Safety Study of SEA-CD40 in Cancer Patients
This study is being done to find out if SEA-CD40 is safe and effective when given alone, in combination with pembrolizumab, and in combination with pembrolizumab, gemcitabine, and nab-paclitaxel.
- Conditions
- Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Hodgkin Disease, Lymphoma
- Trial name
- NCT02376699
- Testing
- Intravenous (IV) SEA-CD40, Pembrolizumab, Subcutaneous (SC) SEA-CD40
- Where
- 19 sites in United States
- Volunteers
- 159 people
- Sponsor
- Seagen Inc.
Solid Tumor, Advanced Cancer
MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors
This is a multipart, open-label, multi-center dose escalation, dose expansion phase I clinical trial designed to evaluate the safety, tolerability, maximum tolerated dose (MTD), recommended phase 2 dose (RP2D), and preliminary…
- Conditions
- Solid Tumor, Advanced Cancer, Metastatic Cancer, Non Small Cell Lung Cancer
- Trial name
- NCT05076760
- Testing
- MEM-288 Intratumoral Injection, Nivolumab, Docetaxel
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Memgen, Inc.
Pancreatic Cancer, Breast Cancer
Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors
Study of NGM438 as Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumors
- Conditions
- Pancreatic Cancer, Breast Cancer, Gastric Cancer, Non Small Cell Lung Cancer
- Trial name
- NCT05311618
- Testing
- NGM438, Pembrolizumab (KEYTRUDA ®)
- Where
- 6 sites in United States
- Volunteers
- 71 people
- Sponsor
- NGM Biopharmaceuticals, Inc
Esophageal Squamous Cell Carcinoma
KN046 in Subjects With Late Stage Esophageal Squamous Cell Carcinoma
This is an open-label, multi-center, single arm study to evaluate the efficacy, safety and tolerability of KN046 in subjects with advanced unresectable or metastatic esophageal squamous cell carcinoma (ESCC).
- Trial name
- NCT03925870
- Testing
- KN046
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Jiangsu Alphamab Biopharmaceuticals Co., Ltd
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.